Katherine M Delaney1, Ronnie Guillet2, Eva K Pressman3, Tomas Ganz4, Elizabeta Nemeth4, Kimberly O O'Brien1. 1. Division of Nutritional Sciences, Cornell University, Ithaca, NY, USA. 2. Department of Pediatrics, Division of Neonatology, University of Rochester School of Medicine, Rochester, NY, USA. 3. Department of Obstetrics and Gynecology, University of Rochester School of Medicine, Rochester, NY, USA. 4. Center for Iron Disorders, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Abstract
BACKGROUND: Maintaining adequate iron status during pregnancy is important for the mother and her developing fetus. Iron homeostasis is influenced by 3 regulatory hormones: erythropoietin (EPO), hepcidin, and erythroferrone (ERFE). To date, normative data on ERFE across pregnancy and its relations to other hormones and iron status indicators are limited. OBJECTIVES: The objective of this study was to characterize maternal ERFE across pregnancy and at delivery and evaluate the utility of hepcidin, ERFE, and EPO in identifying women with increased iron needs. METHODS: ERFE was measured in extant serum samples collected from 2 longitudinal cohorts composed of women carrying multiple fetuses (n = 79) and pregnant adolescents (n = 218) at midgestation (∼26 wk) and delivery (∼39 wk). Receiver operating characteristic curves were generated to characterize the predictive ability of serum ERFE, hepcidin, and EPO and their ratios to identify women at increased risk of iron deficiency and anemia. RESULTS: In these pregnant women, mean ERFE was 0.48 ng/mL at both ∼25 wk of gestation and at delivery. ERFE was positively associated with EPO at midgestation (β = 0.14, P = 0.002, n = 202) and delivery (β = 0.12, P < 0.001, n = 225) but was not significantly associated with maternal hepcidin at any time point surveyed. Of all hormones measured at midgestation and delivery, EPO was best able to identify women with anemia (AUC: 0.86 and 0.75, respectively) and depleted iron stores (AUC: 0.77 and 0.84), whereas the hepcidin-to-EPO ratio was best able to identify women with iron deficiency anemia (AUC: 0.85 and 0.84). CONCLUSIONS: Maternal ERFE was significantly associated with EPO but was not able to identify women with gestational iron deficiency. At term, the hepcidin-to-EPO ratio, an index that accounts for both iron status and erythropoietic demand, and EPO were the strongest indicators of maternal iron deficiency and anemia. This trial was registered at clinicaltrials.gov as NCT04517734 (https://clinicaltrials.gov/ct2/show/NCT04517734).
BACKGROUND: Maintaining adequate iron status during pregnancy is important for the mother and her developing fetus. Iron homeostasis is influenced by 3 regulatory hormones: erythropoietin (EPO), hepcidin, and erythroferrone (ERFE). To date, normative data on ERFE across pregnancy and its relations to other hormones and iron status indicators are limited. OBJECTIVES: The objective of this study was to characterize maternal ERFE across pregnancy and at delivery and evaluate the utility of hepcidin, ERFE, and EPO in identifying women with increased iron needs. METHODS: ERFE was measured in extant serum samples collected from 2 longitudinal cohorts composed of women carrying multiple fetuses (n = 79) and pregnant adolescents (n = 218) at midgestation (∼26 wk) and delivery (∼39 wk). Receiver operating characteristic curves were generated to characterize the predictive ability of serum ERFE, hepcidin, and EPO and their ratios to identify women at increased risk of iron deficiency and anemia. RESULTS: In these pregnant women, mean ERFE was 0.48 ng/mL at both ∼25 wk of gestation and at delivery. ERFE was positively associated with EPO at midgestation (β = 0.14, P = 0.002, n = 202) and delivery (β = 0.12, P < 0.001, n = 225) but was not significantly associated with maternal hepcidin at any time point surveyed. Of all hormones measured at midgestation and delivery, EPO was best able to identify women with anemia (AUC: 0.86 and 0.75, respectively) and depleted iron stores (AUC: 0.77 and 0.84), whereas the hepcidin-to-EPO ratio was best able to identify women with iron deficiency anemia (AUC: 0.85 and 0.84). CONCLUSIONS: Maternal ERFE was significantly associated with EPO but was not able to identify women with gestational iron deficiency. At term, the hepcidin-to-EPO ratio, an index that accounts for both iron status and erythropoietic demand, and EPO were the strongest indicators of maternal iron deficiency and anemia. This trial was registered at clinicaltrials.gov as NCT04517734 (https://clinicaltrials.gov/ct2/show/NCT04517734).
Authors: Yuan Ru; Eva K Pressman; Elizabeth M Cooper; Ronnie Guillet; Philip J Katzman; Tera R Kent; Stephen J Bacak; Kimberly O O'Brien Journal: Am J Clin Nutr Date: 2016-08-31 Impact factor: 7.045
Authors: Chia-Yu Wang; Yang Xu; Lisa Traeger; Deniz Y Dogan; Xia Xiao; Andrea U Steinbicker; Jodie L Babitt Journal: Blood Date: 2020-02-06 Impact factor: 22.113
Authors: Thiago Gagliano-Jucá; Karol M Pencina; Tomas Ganz; Thomas G Travison; Philip W Kantoff; Paul L Nguyen; Mary-Ellen Taplin; Adam S Kibel; Zhuoying Li; Grace Huang; Robert R Edwards; Elizabeta Nemeth; Shehzad Basaria Journal: Am J Physiol Endocrinol Metab Date: 2018-10-16 Impact factor: 4.310
Authors: Sunmin Lee; Ronnie Guillet; Elizabeth M Cooper; Mark Westerman; Mark Orlando; Eva Pressman; Kimberly O O'Brien Journal: J Nutr Date: 2014-07-30 Impact factor: 4.798
Authors: Amat Bah; Sant-Rayn Pasricha; Momodou W Jallow; Ebrima A Sise; Rita Wegmuller; Andrew E Armitage; Hal Drakesmith; Sophie E Moore; Andrew M Prentice Journal: J Nutr Date: 2017-04-19 Impact factor: 4.798
Authors: Veena Sangkhae; Vivian Yu; Richard Coffey; Kimberly O O'Brien; Tomas Ganz; Elizabeta Nemeth Journal: Am J Hematol Date: 2022-08-16 Impact factor: 13.265
Authors: Ramón Figueroa-Mujica; Luis Angel Ccahuantico; Maycol Suker Ccorahua-Rios; Juan José Sanchez-Huaman; Cinthya Vásquez-Velasquez; Jorge M Ponce-Huarancca; Rodrigo E Rozas-Gamarra; Gustavo F Gonzales Journal: Life (Basel) Date: 2022-05-13